Cystic fibrosis sputum: a barrier to the transport of nanospheres.

Cystic fibrosis (CF) is characterized by the presence of a viscoelastic mucus layer in the upper airways and bronchi. The underlying problem is a mutation in the gene encoding the cystic fibrosis transmembrane conductance regulator protein. Clinical studies of gene transfer for CF are ongoing. For gene delivery to the airways of CF patients to be effective, the mucus covering the target cells must be overcome. We therefore examined the extent to which CF sputum presents a physical barrier to the transport of nanospheres of a size comparable to that of lipoplexes and other transfection systems currently being clinically evaluated for CF gene therapy. We observed that an extremely low percentage of nanospheres (< 0.3%) moved through a 220-microm-thick CF sputum layer after 150 min. The largest nanospheres studied (560 nm) were almost completely blocked by the sputum, whereas the smaller nanospheres (124 nm) were retarded only by a factor of 1.3 as compared with buffer. Surprisingly, the nanospheres diffused significantly more easily through the more viscoelastic sputum samples. We hypothesize that the structure of the network in sputum becomes more macroporous when the sputum becomes more viscoelastic. Sputum from a patient with chronic obstructive pulmonary disease retarded the transport of nanospheres to the same extent as did CF sputum. When directly mixed with CF sputum, recombinant human deoxyribonuclease I moderately facilitated the transport of nanospheres through CF sputum.

[1]  D. Geddes,et al.  Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG5000 formulation to the lungs of normal volunteers , 1997, Gene Therapy.

[2]  P. Renesto,et al.  Inhibition by recombinant SLPI and half‐SLPI (Asn55‐Ala107) of elastase and cathepsin G activities: consequence for neutrophil‐platelet cooperation , 1993, British journal of pharmacology.

[3]  R. Boucher,et al.  Status of gene therapy for cystic fibrosis lung disease. , 1999, The Journal of clinical investigation.

[4]  E. Alton,et al.  The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro , 1998, Gene Therapy.

[5]  J M Zahm,et al.  Role of the physicochemical properties of mucus in the protection of the respiratory epithelium , 2012 .

[6]  J. Miquel,et al.  Quantification of mucin in human gallbladder bile: a fast, specific, and reproducible method. , 1995, Journal of lipid research.

[7]  S. Ferrari,et al.  ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo , 1997, Gene Therapy.

[8]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[9]  J. Harper,et al.  Active site mapping of the serine proteases human leukocyte elastase, cathepsin G, porcine pancreatic elastase, rat mast cell proteases I and II. Bovine chymotrypsin A alpha, and Staphylococcus aureus protease V-8 using tripeptide thiobenzyl ester substrates. , 1984, Biochemistry.

[10]  A. I. Yudin,et al.  Human cervical mucus and its interaction with sperm: a fine-structural view. , 1989, Biology of reproduction.

[11]  K. Whaley,et al.  Antibody diffusion in human cervical mucus. , 1994, Biophysical journal.

[12]  S. Shak,et al.  Effects of rhDNase on purulent airway secretions in chronic bronchitis. , 1996, The European respiratory journal.

[13]  D. Scherman,et al.  Lipospermine-based gene transfer into the newborn mouse brain is optimized by a low lipospermine/DNA charge ratio. , 1995, Human gene therapy.

[14]  P. Janmey,et al.  Actin filaments mediate DNA fiber formation in chronic inflammatory airway disease. , 1996, The American journal of pathology.

[15]  R. Scheule,et al.  Biophysical characterization of cationic lipid: DNA complexes. , 1997, Biochimica et biophysica acta.

[16]  A. Daugherty,et al.  Distribution of DNA and alginate in purulent cystic fibrosis sputum: implications to pulmonary targeting strategies. , 1996, Journal of drug targeting.

[17]  L. Szentkuti,et al.  Light microscopical observations on luminally administered dyes, dextrans, nanospheres and microspheres in the pre-epithelial mucus gel layer of the rat distal colon , 1997 .

[18]  Alton,et al.  Cystic fibrosis clinical trials. , 1998, Advanced drug delivery reviews.

[19]  T. Meyvis,et al.  Diffusion of Macromolecules in Dextran Methacrylate Solutions and Gels As Studied by Confocal Scanning Laser Microscopy , 1997 .

[20]  Patrick J. Sinko,et al.  Effect of size, surface charge, and hydrophobicity on the translocation of polystyrene microspheres through gastrointestinal mucin , 1997 .

[21]  J. Hoidal,et al.  Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. , 1988, The Journal of clinical investigation.

[22]  K. Nakajima,et al.  Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase. Studies with peptide substrates related to the alpha 1-protease inhibitor reactive site. , 1979, The Journal of biological chemistry.

[23]  P. Cullis,et al.  Nomenclature for synthetic gene delivery systems. , 1997, Human gene therapy.

[24]  C. Galabert,et al.  Functions of proteins and lipids in airway secretions. , 1992, The European respiratory journal.

[25]  F. Horkay,et al.  Scattering and swelling properties of inhomogeneous polyacrylamide gels , 1989 .

[26]  S. Durham,et al.  Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial , 1999, The Lancet.

[27]  D. Geddes,et al.  The extra- and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium , 1999, Gene Therapy.

[28]  Leaf Huang,et al.  Lipidic vector systems for gene transfer. , 1997, Critical reviews in therapeutic drug carrier systems.

[29]  J. Zahm,et al.  Phospholipid composition and surface‐active properties of tracheobronchial secretions from patients with cystic fibrosis and chronic obstructive pulmonary diseases , 1992, Pediatric pulmonology.